Related references
Note: Only part of the references are listed.Wild-type and mutant p53 mediate cisplatin resistance through interaction and inhibition of active caspase-9
Jacqueline L. Y. Chee et al.
CELL CYCLE (2013)
Molecular Pathways: JAK/STAT Pathway: Mutations, Inhibitors, and Resistance
Alfonso Quintas-Cardama et al.
CLINICAL CANCER RESEARCH (2013)
A genetic and developmental pathway from STAT3 to the OCT4-NANOG circuit is essential for maintenance of ICM lineages in vivo
Dang Vinh Do et al.
GENES & DEVELOPMENT (2013)
Cancerous ovarian stem cells: Obscure targets for therapy but relevant to chemoresistance
Nuzhat Ahmed et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2013)
Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden
Khalid Abubaker et al.
MOLECULAR CANCER (2013)
Flow induces epithelial-mesenchymal transition, cellular heterogeneity and biomarker modulation in 3D ovarian cancer nodules
Imran Rizvi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research
Nuzhat Ahmed et al.
FRONTIERS IN ONCOLOGY (2013)
Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research
Emma Kipps et al.
NATURE REVIEWS CANCER (2013)
ALDH1-Bright Epithelial Ovarian Cancer Cells Are Associated with CD44 Expression, Drug Resistance, and Poor Clinical Outcome
Yu-Chi Wang et al.
AMERICAN JOURNAL OF PATHOLOGY (2012)
Diindolylmethane suppresses ovarian cancer growth and potentiates the effect of cisplatin in tumor mouse model by targeting signal transducer and activator of transcription 3 (STAT3)
Prabodh K. Kandala et al.
BMC MEDICINE (2012)
Ovarian cancer stem cell markers: Prognostic and therapeutic implications
Daniela Burgos-Ojeda et al.
CANCER LETTERS (2012)
Stem Cell Pathways Contribute to Clinical Chemoresistance in Ovarian Cancer
Adam D. Steg et al.
CLINICAL CANCER RESEARCH (2012)
DIMming Ovarian Cancer Growth
Prabodh K. Kandala et al.
CURRENT DRUG TARGETS (2012)
Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer
Marta De Donato et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2012)
Targeting the Interleukin-6/Jak/Stat Pathway in Human Malignancies
Pasquale Sansone et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Gene expression analysis of matched ovarian primary tumors and peritoneal metastasis
Joel A. Malek et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Identification of a Potential Ovarian Cancer Stem Cell Gene Expression Profile from Advanced Stage Papillary Serous Ovarian Cancer
Vinod Vathipadiekal et al.
PLOS ONE (2012)
Isolation and Characterization of Tumor Cells from the Ascites of Ovarian Cancer Patients: Molecular Phenotype of Chemoresistant Ovarian Tumors
Ardian Latifi et al.
PLOS ONE (2012)
Overcoming Challenges of Ovarian Cancer Stem Cells: Novel Therapeutic Approaches
Cristobal Aguilar-Gallardo et al.
STEM CELL REVIEWS AND REPORTS (2012)
Absolute requirement for STAT3 function in small-intestine crypt stem cell survival
J. R. Matthews et al.
CELL DEATH AND DIFFERENTIATION (2011)
MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis
Catherine Theriault et al.
GYNECOLOGIC ONCOLOGY (2011)
Cisplatin Treatment of Primary and Metastatic Epithelial Ovarian Carcinomas Generates Residual Cells With Mesenchymal Stem Cell-Like Profile
Ardian Latifi et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2011)
The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells
K. A. Monaghan et al.
LEUKEMIA (2011)
Ovarian Cancer Development and Metastasis
Ernst Langyel
AMERICAN JOURNAL OF PATHOLOGY (2010)
CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms
Jeffrey W. Tyner et al.
BLOOD (2010)
Epithelial Mesenchymal Transition and Cancer Stem Cell-Like Phenotypes Facilitate Chemoresistance in Recurrent Ovarian Cancer
N. Ahmed et al.
CURRENT CANCER DRUG TARGETS (2010)
CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells
M-Q Gao et al.
ONCOGENE (2010)
Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas
M. Colomiere et al.
BRITISH JOURNAL OF CANCER (2009)
Molecular phenotyping of human ovarian cancer stem cells unravel the mechanisms for repair and chemo-resistance
Ayesha B. Alvero et al.
CELL CYCLE (2009)
Multicellular spheroids in ovarian cancer metastases: Biology and pathology
Kristy Shield et al.
GYNECOLOGIC ONCOLOGY (2009)
Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion
Francis Rodier et al.
NATURE CELL BIOLOGY (2009)
STAT3 Is Required for Proliferation and Maintenance of Multipotency in Glioblastoma Stem Cells
Maureen M. Sherry et al.
STEM CELLS (2009)
IL-4-mediated drug resistance in colon cancer stem cells
Matilde Todaro et al.
CELL CYCLE (2008)
Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression
Laurie G. Hudson et al.
CLINICAL & EXPERIMENTAL METASTASIS (2008)
STAT3 as a target for cancer drug discovery
Luca Costantino et al.
CURRENT MEDICINAL CHEMISTRY (2008)
Expression and activity of taxane-metobolizing enzymes in ovarian tumors
Julie A. DeLoia et al.
GYNECOLOGIC ONCOLOGY (2008)
Chemotherapeutic drugs and human tumor cells cytokine network
Vera Levina et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Expression of CD133-1 and CD133-2 in ovarian cancer
G. Ferrandina et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2008)
Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells
Lilly Y. W. Bourguignon et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
ABCB1 G1199A polymorphism and ovarian cancer response to paclitaxel
Henrik Green et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2008)
Epithelial-mesenchymal interconversions in normal ovarian surface epithelium and ovarian carcinomas: An exception to the norm
Nuzhat Ahmed et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2007)
Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4
Matilde Todaro et al.
CELL STEM CELL (2007)
The role of constitutively active signal transducer and activator of transcription 3 in ovarian turnorigenesis and prognosis
Daniel G. Rosen et al.
CANCER (2006)
Mechanisms of transcoelomic metastasis in ovarian cancer
David S. P. Tan et al.
LANCET ONCOLOGY (2006)
DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy
Ken A. Olaussen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness
Paul P. Szotek et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Systemic therapy for ovarian cancer: Current status and new treatments
Robert F. Ozols
SEMINARS IN ONCOLOGY (2006)
Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers
KM Burleson et al.
GYNECOLOGIC ONCOLOGY (2004)
Ovarian carcinoma spheroids disaggregate on type I collagen and invade live human mesothelial cell monolayers
KM Burleson et al.
CLINICAL & EXPERIMENTAL METASTASIS (2004)
Reversal of acquired cisplatin resistance by modulation of metallothionein in transplanted murine tumors
Y Saga et al.
INTERNATIONAL JOURNAL OF UROLOGY (2004)
Mechanisms of paclitaxel-induced apoptosis in an ovarian cancer cell line and its paclitaxel-resistant clone
M Sugimura et al.
ONCOLOGY (2004)
β1-integrins regulate the formation and adhesion of ovarian carcinoma multicellular spheroids
RC Casey et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors
T Hirano et al.
ONCOGENE (2000)
Share Paper
